Medican Enterprises Appoints Wayne Hansen as CFO

LAS VEGAS--(BUSINESS WIRE)--Medican Enterprises Inc. (OTCBB: MDCN), a leading developer, distributor and marketer of pharmaceutical grade cannabis, is pleased to announce the appointment of Wayne Hansen to the position Chief Financial Officer, effective February 19, 2014.

Wayne Hansen is a highly skilled tax and business consultant with more than 30 years of experience. Since 1996, Mr. Hansen held the position of President at Caulfield Capital Management Inc. where he provided management consulting services to entrepreneurs and businesses with a particular focus on capital formation and acquisition. From 1984 to 1986, Mr. Hansen held various positions at the accounting firm BDO Dunwoody, including Vancouver office managing partner, Asia liaison partner, national firm's committee partner and practice manager. Whilst at BDO Dunwoody, Mr. Hansen was elected to the esteemed position of National Executive Committee Member. Mr. Hansen has a B.A from the University of British Columbia and is a Chartered Accountant. Mr. Hansen has vast experience in the public sector serving as director, treasurer and executive officer for several public companies.

"We are very pleased to welcome Mr. Hansen to our growing team," stated Ken Williams, CEO of Medican Enterprises. "Wayne brings more than 30 years experience across the business and financial sectors. His proven ability in corporate financial management, capital formation and acquisition are a great match for Medican's scalable business model. We look forward to his valuable contributions, which certainly will prove instrumental as the Company moves forward."

"The industry leaders in the growing medical marijuana sector must fulfill rigorous federal requirements and be able to scale quickly as the medical marijuana market matures," said Mr. Hansen, CFO of Medican Enterprises. "Medican Enterprises is poised to capitalize on this opportunity. Through its agile business model and joint venture solutions, Medican will maximize shareholder value and capital gain without funding or consequent share dilution."

About the Medical Marijuana Industry

Health Canada projects a $1.3 billion medial marijuana market by 2024. Medican is uniquely positioned in the emerging medical marijuana industry and is poised to begin development of Medical Marijuana and Cultivation Centres across Canada and the United States. Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.medicaninc.com.

About Medican Enterprises Inc.

Medican Enterprises is a bio-pharmaceutical company focused on developing, distributing and marketing pharmaceutical grade cannabis to the emerging global medical marijuana market. It's wholly owned subsidiary Medican Systems Inc. is an industry leader in the design, construction and operation of Medical Marijuana and Cultivation Centers across Canada and the United States. Traded on the OTCBB, Medican drives shareholder value through its scalable business model and commitment to scientific research, operational excellence and regulatory compliance. For more information visit: www.medicaninc.com.

Forward-Looking and Cautionary Statements

Certain statements contained herein contain "forward-looking statements" within the meaning of Section 27A of Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medican Enterprises Inc., to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Medican Enterprises Inc. disclaims any obligation to update or to announce publicly the results of any revision of the forward-looking statements contained or incorporated by reference herein to reflect future events or developments. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Contacts

Medican Enterprises Inc.
Ken Williams, CEO
T: +1-800-416-8802
E: [email protected]

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.